PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Nerandomilast (Jascayd)

Status:

To Patients

Condition:

Other ILD

Intervention Type:

Oral Drug

Funder Type:

Industry

Drug Detail

Nerandomilast (Jascayd) is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects.

Find a Clinical Trial

Latest News on Nerandomilast (Jascayd)

Feb

10

2025

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Learn More Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Feb

24

2022

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Learn More FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

Drug

Drug Detail

Latest News on Nerandomilast (Jascayd)

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis